TaiMed Biologics Total Assets
TaiMed Biologics total assets. Based on the latest financial reports, TaiMed Biologics (4147) holds total assets worth NT$4.50 Billion TWD (≈ $141.81 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TaiMed Biologics market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of TaiMed Biologics (2009–2025)
Total assets of TaiMed Biologics from 2009 to 2025. This chart illustrates how TaiMed Biologics's total assets have evolved over time, based on quarterly financial data. See TaiMed Biologics stock quote for real-time trading data and today's change.
TaiMed Biologics - Asset Composition Analysis
TaiMed Biologics Total Assets Breakdown (December 2025)
TaiMed Biologics total assets breakdown as of December 2025. TaiMed Biologics's total assets of NT$4.50 Billion consist of 69.1% current assets and 30.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 18.7% |
| Accounts Receivable | NT$64.65 Million | 1.3% |
| Inventory | NT$827.73 Million | 17.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$442.15 Million | 9.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how TaiMed Biologics's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 4147 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TaiMed Biologics's current assets represent 69.1% of total assets in 2025, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 18.7% of total assets in 2025, down from 43.8% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 36.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 17.2% of total assets.
TaiMed Biologics Competitors by Total Assets
Key competitors of TaiMed Biologics based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
TaiMed Biologics - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 15.48 | 24.39 | 23.15 |
| Quick Ratio | 11.72 | 17.71 | 11.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.86 Billion | NT$3.12 Billion | NT$2.31 Billion |
TaiMed Biologics - Advanced Valuation Insights
This section examines the relationship between TaiMed Biologics's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.62 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -3.8% |
| Total Assets | NT$4.81 Billion |
| Market Capitalization | $472.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values TaiMed Biologics's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: TaiMed Biologics's assets decreased by 3.8% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for TaiMed Biologics (2009–2025)
The table below shows the annual total assets of TaiMed Biologics from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$4.81 Billion ≈ $151.56 Million |
-3.77% |
| 2024-12-31 | NT$5.00 Billion ≈ $157.50 Million |
+28.39% |
| 2023-12-31 | NT$3.89 Billion ≈ $122.68 Million |
-5.05% |
| 2022-12-31 | NT$4.10 Billion ≈ $129.21 Million |
-11.05% |
| 2021-12-31 | NT$4.61 Billion ≈ $145.26 Million |
-11.27% |
| 2020-12-31 | NT$5.20 Billion ≈ $163.71 Million |
+9.84% |
| 2019-12-31 | NT$4.73 Billion ≈ $149.04 Million |
-1.26% |
| 2018-12-31 | NT$4.79 Billion ≈ $150.94 Million |
+6.40% |
| 2017-12-31 | NT$4.50 Billion ≈ $141.87 Million |
-6.22% |
| 2016-12-31 | NT$4.80 Billion ≈ $151.28 Million |
-2.53% |
| 2015-12-31 | NT$4.93 Billion ≈ $155.21 Million |
+161.95% |
| 2014-12-31 | NT$1.88 Billion ≈ $59.25 Million |
+163.14% |
| 2013-12-31 | NT$714.72 Million ≈ $22.52 Million |
+8.38% |
| 2012-12-31 | NT$659.45 Million ≈ $20.78 Million |
-22.82% |
| 2011-12-31 | NT$854.39 Million ≈ $26.92 Million |
-19.25% |
| 2010-12-31 | NT$1.06 Billion ≈ $33.33 Million |
+71.42% |
| 2009-12-31 | NT$617.22 Million ≈ $19.45 Million |
-- |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more